title: Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.
abstract: BACKGROUND
  The aim of our prospective multicenter Clopidogrel Registry was to evaluate the efficacy and safety of a 300-mg loading dose of clopidogrel at the time of ad hoc stenting in patients with suspected coronary artery disease who were not pretreated with clopidogrel for any reason, and to compare the 30-day clinical event rates with the outcome of patients pretreated with a loading dose of clopidogrel 6 to 24 hours before stenting.
  
  
  METHODS
  Between March 2002 and February 2004, 4160 consecutively included patients received a 300-mg loading dose of clopidogrel immediately after (group 1, n = 2679) or 6 to 24 hours before stenting (group 2, n = 1481).
  
  
  RESULTS
  The primary end point (triple composite end point of acute myocardial infarction, all-cause death, and urgent repeat target vessel revascularization) at 30 days occurred in 4.74% versus 2.77% in groups 1 and 2, respectively (P = .002). The secondary end point events, the stent thrombosis, occurred significantly more frequently in group 1, with a trend toward increase in incidence of death, target vessel revascularization, or need for glycoprotein IIb/IIIa antagonists during percutaneous coronary intervention. Pretreatment with clopidogrel was associated with more major bleeding (secondary safety end point) (0.41% vs 1.35% in groups 1 and 2, respectively; P = .001).
  
  
  CONCLUSIONS
  The results of our multicenter prospective Clopidogrel Registry demonstrate lower efficacy of a 300-mg loading dose of clopidogrel at the time of stenting compared with pretreatment 6 to 24 hours before percutaneous coronary intervention on the 30-day composite clinical end point in the large unselected patient cohort, which suggests the benefit of clopidogrel pretreatment in all incoming patients with suspected significant coronary artery disease scheduled for coronary angiography.
authors.affiliation: Department of Cardiology, Medical University of Vienna, Vienna, Austria.
authors.forename: Tibor
authors.initials: T
authors.lastname: Szük
authors.forename: Mariann
authors.initials: M
authors.lastname: Gyöngyösi
authors.forename: Nóra
authors.initials: N
authors.lastname: Homorodi
authors.forename: Eva
authors.initials: E
authors.lastname: Kristóf
authors.forename: Csaba
authors.initials: C
authors.lastname: Király
authors.forename: István F
authors.initials: IF
authors.lastname: Edes
authors.forename: Andrea
authors.initials: A
authors.lastname: Facskó
authors.forename: Noemi
authors.initials: N
authors.lastname: Pavo
authors.forename: Gottfried
authors.initials: G
authors.lastname: Sodeck
authors.forename: Christoph
authors.initials: C
authors.lastname: Strehblow
authors.forename: Serdar
authors.initials: S
authors.lastname: Farhan
authors.forename: Gerald
authors.initials: G
authors.lastname: Maurer
authors.forename: Dietmar
authors.initials: D
authors.lastname: Glogar
authors.forename: Hans
authors.initials: H
authors.lastname: Domanovits
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
authors.forename: István
authors.initials: I
authors.lastname: Edes
mesh_terms: D000077144:Clopidogrel; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000601:surgery*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011300:Preoperative Care; D011446:Prospective Studies; D012042:Registries; D015607:Stents; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine